$SCTPF
Stem Cell Therapy Global Market Forecast (2014-2020)
PR Newswire - Tue Sep 08, 8:23PM CDT
Hoovers Research analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis.
Avivagen Announces Two Appointments to its Board of Directors, Mr. David Allan and Ms. Vanessa Grant
ACCESSWIRE - Thu May 14, 6:34AM CDT
OTTAWA, ON/ ACCESSWIRE / May 14 2015 / Avivagen Inc. (TSXV:VIV, PINKSHEETS:CHEXF), a life sciences company that develops and delivers products that support and enhance the health of livestock, pets and people, announces the appointment of two new Directors, Mr. David Allan and Ms. Vanessa Grant, and the resignation of two past Directors, Dr. Janusz Daroszewski and Dr. Chandra Panchal.
Stem Cell Therapeutics Markets
PR Newswire - Tue Feb 10, 12:08PM CST
There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells have become effective tools in blood diseases, musculoskeletal diseases, digestive disorders and many other areas.
Trillium Therapeutics to List Common Shares on the NASDAQ Capital Market Under the Symbol TRIL
GlobeNewswire - Thu Dec 18, 6:00AM CST
Trillium Therapeutics Inc. ("Trillium"
(TSX:TR) (OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its common shares have been approved for listing on the NASDAQ Capital Market under the symbol "TRIL". Trading will commence on or around December 19. The Company will retain its listing on the Toronto Stock Exchange (TSX) under the symbol "TR".
TR.TO: 13.59 (-0.31)
Stem Cell Therapeutics Markets: 2014 Report
PR Newswire - Mon Nov 17, 6:28AM CST
DUBLIN, Nov. 17, 2014 Research and Markets has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering.
Research and Markets: Stem Cell Therapeutics Markets Report 2014: Current Technology Performance, New Developments, Pricing Trends and Government Positions
BusinessWire - Mon Nov 17, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/dwcl2d/stem_cell) has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering.
Stem Cell Therapeutics Markets Report 2014: Current Technology Performance, New Developments, Pricing Trends and Government Positions
M2 - Mon Nov 17, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/qqvpmm/stem_cell) has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering. There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells have become effective tools in blood diseases, musculoskeletal diseases, digestive disorders and many other areas. Stem Cell Therapeutics Markets conducts in-depth research into the stem cell market opportunity by assessing current technology performance, new developments, pricing trends and government positions on the topic. A combination approach - using both a bottom-up model and comparing data with a top-down analysis - was used to determine market size and market forecasts. Over the next several years, as researchers introduce a growing variety of technologies, products and services based upon stem cells, revenues related to stem cell therapies will increase dramatically. New therapeutic applications of stem cells could potentially be realized in all of the following disease segments: - Blood and Blood-Forming Organs - Circulatory System - Endocrine and Metabolic System and Immunity Disorders - Eye - Gastrointestinal System - Musculoskeletal System and Connective Tissue Disorders - Neoplasms - Nervous System - Respiratory System - Skin and Subcutaneous Tissues Key Topics Covered: One: Executive Summary Two: Stem Cells: An Introduction Three: Regulatory Landscape And Research Policy Four: Development Profiles And Analysis Five: Therapeutic Applications: Current And Potential Stem Cell Segments Six: Stem Cell Market Summary And Outlook Appendix: Industry Participants For more information visit http://www.researchandmarkets.com/research/qqvpmm/stem_cell
Trillium Therapeutics Provides Corporate Update and Announces Reverse Stock Split for NASDAQ Listing
GlobeNewswire - Thu Nov 13, 6:00AM CST
Trillium Therapeutics Inc. ("Trillium" (TSX:TR) (OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today provided the following corporate update:
TR.TO: 13.59 (-0.31)
Report: Stem Cell Technologies Market Growing
PR Newswire - Fri Oct 31, 6:13AM CDT
Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets. This includes revenues from proprietary stem cell therapeutics that have gained or are expected to gain approval from respected regulatory authorities.
Stem Cell Therapy Global Market Forecast (2014-2020)
PR Newswire - Tue Sep 08, 8:23PM CDT
Hoovers Research analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis.
Avivagen Announces Two Appointments to its Board of Directors, Mr. David Allan and Ms. Vanessa Grant
ACCESSWIRE - Thu May 14, 6:34AM CDT
OTTAWA, ON/ ACCESSWIRE / May 14 2015 / Avivagen Inc. (TSXV:VIV, PINKSHEETS:CHEXF), a life sciences company that develops and delivers products that support and enhance the health of livestock, pets and people, announces the appointment of two new Directors, Mr. David Allan and Ms. Vanessa Grant, and the resignation of two past Directors, Dr. Janusz Daroszewski and Dr. Chandra Panchal.
Stem Cell Therapeutics Markets
PR Newswire - Tue Feb 10, 12:08PM CST
There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells have become effective tools in blood diseases, musculoskeletal diseases, digestive disorders and many other areas.
Trillium Therapeutics to List Common Shares on the NASDAQ Capital Market Under the Symbol TRIL
GlobeNewswire - Thu Dec 18, 6:00AM CST
Trillium Therapeutics Inc. ("Trillium"
(TSX:TR) (OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its common shares have been approved for listing on the NASDAQ Capital Market under the symbol "TRIL". Trading will commence on or around December 19. The Company will retain its listing on the Toronto Stock Exchange (TSX) under the symbol "TR". TR.TO: 13.59 (-0.31)
Stem Cell Therapeutics Markets: 2014 Report
PR Newswire - Mon Nov 17, 6:28AM CST
DUBLIN, Nov. 17, 2014 Research and Markets has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering.
Research and Markets: Stem Cell Therapeutics Markets Report 2014: Current Technology Performance, New Developments, Pricing Trends and Government Positions
BusinessWire - Mon Nov 17, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/dwcl2d/stem_cell) has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering.
Stem Cell Therapeutics Markets Report 2014: Current Technology Performance, New Developments, Pricing Trends and Government Positions
M2 - Mon Nov 17, 4:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/qqvpmm/stem_cell) has announced the addition of the "Stem Cell Therapeutics Markets" report to their offering. There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells have become effective tools in blood diseases, musculoskeletal diseases, digestive disorders and many other areas. Stem Cell Therapeutics Markets conducts in-depth research into the stem cell market opportunity by assessing current technology performance, new developments, pricing trends and government positions on the topic. A combination approach - using both a bottom-up model and comparing data with a top-down analysis - was used to determine market size and market forecasts. Over the next several years, as researchers introduce a growing variety of technologies, products and services based upon stem cells, revenues related to stem cell therapies will increase dramatically. New therapeutic applications of stem cells could potentially be realized in all of the following disease segments: - Blood and Blood-Forming Organs - Circulatory System - Endocrine and Metabolic System and Immunity Disorders - Eye - Gastrointestinal System - Musculoskeletal System and Connective Tissue Disorders - Neoplasms - Nervous System - Respiratory System - Skin and Subcutaneous Tissues Key Topics Covered: One: Executive Summary Two: Stem Cells: An Introduction Three: Regulatory Landscape And Research Policy Four: Development Profiles And Analysis Five: Therapeutic Applications: Current And Potential Stem Cell Segments Six: Stem Cell Market Summary And Outlook Appendix: Industry Participants For more information visit http://www.researchandmarkets.com/research/qqvpmm/stem_cell
Trillium Therapeutics Provides Corporate Update and Announces Reverse Stock Split for NASDAQ Listing
GlobeNewswire - Thu Nov 13, 6:00AM CST
Trillium Therapeutics Inc. ("Trillium"
(TSX:TR) (OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today provided the following corporate update: TR.TO: 13.59 (-0.31)
Report: Stem Cell Technologies Market Growing
PR Newswire - Fri Oct 31, 6:13AM CDT
Though therapies are in their nascent phase, sales of stem cell technologies are expected to show an annual increase of 16.2% over the 2010-2020 period, reaching an expected market value of nearly $1 billion, according to Kalorama Information's report, Stem Cell Therapeutics Markets. This includes revenues from proprietary stem cell therapeutics that have gained or are expected to gain approval from respected regulatory authorities.
